Technical analysis of Prelude Therapeutics Incorporated (PRLD): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Price Performance
| 1 month | -22.26% |
| 3 months | +3.47% |
| Year-to-date | +54.14% |
| 1 year | +329.81% |
| 3 years | +41.01% |
| 5 years | -87.30% |
52-Week Range
| 52-week High | $6.83 |
| 52-week Low | $0.98 |
| Avg Volume (90d) | 447K |
Technical Indicators
| SMA 50 | $5.02 |
| SMA 200 | $3.73 |
| Beta | 0.71 |
| 30-day Volatility (annualised) | 80.4% |
| Price vs SMA 50 | -11.0% |
| Price vs SMA 200 | +19.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.59 | |
| 2025-11 | $1.68 | +5.7% |
| 2025-12 | $2.90 | +72.6% |
| 2026-01 | $1.85 | -36.2% |
| 2026-02 | $2.76 | +49.2% |
| 2026-03 | $3.42 | +23.9% |
| 2026-04 | $5.23 | +52.9% |
| 2026-05 | $3.92 | -25.0% |
| 2026-06 | $5.33 | +36.0% |
| 2026-07 | $4.60 | -13.7% |
| 2026-08 | $5.60 | +21.7% |
| 2026-09 | $4.47 | -20.2% |
Price
| Price | $4.47 |
| Market Cap | $254M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.13 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 4.07 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.34 |